<DOC>
	<DOCNO>NCT00289601</DOCNO>
	<brief_summary>This study randomize , double-blind , multi-center study design compare difference rate myonecrosis ( measure elevation CK-MB ratio ≥ 2 time ULN ) within 24 hour follow low-medium risk percutaneous coronary intervention ( PCI ) aspirin clopidogrel non-responsive patient randomize heparin without eptifibatide therapy PCI . The primary objective study determine use eptifibatide associate significant difference post-PCI myonecrosis ( measure elevation CK-MB ratio ≥ 2 time upper limit normal [ ULN ] ) within 24 hour low-medium risk PCI patient aspirin non-responsive determine VerifyNow Aspirin P2Y12 testing .</brief_summary>
	<brief_title>Randomized Study Aspirin Resistant Patients Undergoing Angioplasty</brief_title>
	<detailed_description>The primary objective study determine use eptifibatide associate significant difference post-PCI myonecrosis ( measure elevation CK-MB ratio ≥ 2 time upper limit normal [ ULN ] ) within 24 hour low-medium risk PCI patient aspirin clopidogrel non-responsive determine VerifyNow Aspirin P2Y12 test . Secondary study objective include assessment safety . These safety determination determine monitor rate MACE ( define death , MI , ischemic [ non-hemorrhagic ] stroke urgent revascularization repeat PCI CABG ) , bleed event , rate bailout procedure perform , elevation CK-MB ratio ( range 3 5 time ULN great 5 time ULN ) elevations troponin I . This study randomize , double-blind , multi-center study design compare difference rate myonecrosis ( measure elevation CK-MB ratio ≥ 2 time ULN ) within 24 hour follow low-medium risk percutaneous coronary intervention ( PCI ) aspirin clopidogrel non-responsive patient randomize heparin without eptifibatide therapy PCI . All subject must also pretreated clopidogrel ( 300-600 mg ) least 2 hour PCI . Study subject randomize either eptifibatide unfractionated heparin unfractionated heparin placebo . Study subject randomization aspirin non-responsive patient stratify base upon clopidogrel responsiveness .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<criteria>Patients coronary artery disease eligible study . Inclusion criterion : Patient 21 year old . Patient schedule undergo lowmedium risk percutaneous coronary intervention native coronary vessel . Patient selfreports he/she receive aspirin ≥ 81 mg least 4 hour prior study screen . Patient define aspirin nonresponsive base upon result VerifyNow™ Aspirin test , define aspirin reaction unit ( ARU ) &gt; 475 . Patient define clopidogrel nonresponsive base upon result VerifyNow P2Y12 test , define less 20 % inhibition . Patient treat 300 600 mg clopidogrel least two hour intervention . All patient provide write informed consent , study protocol approve IRB participate center . Patient male , nonpregnant female . Patient know allergic reaction study medication . Patient diagnose myocardial infarction within prior 7 day . Patient unstable angina , define dynamic , ischemic ECG change ( STsegment elevation , STsegment depression , Twave inversion ) rest . Patient rest pain leave bundle branch block . Note : In patient rest pain abnormal ECG believe nonacute ( i.e. , STTW abnormalities secondary LVH , digoxin , prior remote infarction ) , second electrocardiogram 30 min apart require establish change nondynamic indicative active ischemia . The target lesion ( ) locate venous bypass graft . The patient chronic occlusion ( present longer 3 month ) . The target lesion ( ) visible thrombus ( angiography ) . The patient suspect aortic dissection . Patient leave ventricular ejection ( LVEF ) &lt; 30 % . Patient receive oral anticoagulation therapy . Patient receive follow drug 7 day prior enrollment : GP IIb/IIIa inhibitor ticlopidine dipyridamole cilostazol ( Pletal ) Patient receive nonsteroidal antiinflammatory drug ( NSAIDS ) , steroidal drug 24 hour prior enrollment . Patient diagnose stroke within prior 3 month . Patient active bleeding bleed diathesis . Patient experience trauma major surgery precede month . Patient severe , uncontrolled hypertension ( systolic blood pressure 180 mm Hg ) . Patient ’ creatinine &gt; 2.0 mg/dl prior PCI . Patient hemoglobin level le 10.0 g per deciliter hematocrit 30 percent . Patient platelet count le 100,000 per cubic millimeter 600,000 per cubic millimeter . Of note , patient chronic clopidogrel eligible VerifyNow P2Y12 test . Clopidogrel nonresponsiveness group define &lt; 20 % inhibition</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>aspirin</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>resistance</keyword>
	<keyword>angioplasty</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>myocardial infarction</keyword>
</DOC>